Creo Medical Share Price – Live Quote, News and Analysis

Creo Medical Group PLC (LON: CREO) currently trades between 13.75p and 14.25p on the London Stock Exchange, reflecting significant volatility within a 52-week band of 9.22p to 37.00p. The Chepstow-based medical technology firm, which develops advanced energy devices for minimally invasive surgery, commands a market capitalization of approximately £70.64 million across 412.47 million outstanding shares.

Recent sessions have registered intraday swings between 13.50p and 14.50p, with trading volume spiking to 3.76 million shares amid noted pre-market interest from US investors. The company reports no dividend yield and carries no price-to-earnings ratio due to operational losses, though first-half 2025 results show cash reserves strengthening to £20.5 million.

What is the current Creo Medical share price?

According to Hargreaves Lansdown, the stock has experienced significant volatility, trading in a 52-week range of 9.22p to 37.00p. Data from the Morningstar platform indicates the shares currently exhibit no dividend yield and lack a normalized P/E ratio due to negative trailing twelve-month earnings.

• Shares trade in the lower portion of a wide upward channel with technical support near 12.40p
• Late-day transactions worth £30,000 to £46,000 suggest institutional accumulation patterns
• US pre-market buying interest has driven recent volume spikes from 11:30 GMT
• Current ratio of 2.75 indicates adequate short-term liquidity despite operational losses
• Revenue increased 40% to £2.2 million in H1’25 compared to £1.6 million prior year
• Operating losses narrowed to £6.9 million from £12.1 million year-over-year
• Barchart data confirms negative returns on assets (-35.51%) and equity (-64.56%)

How has the Creo Medical share price performed historically?

Volatility and Trading Range

Over the past twelve months, Creo Medical shares have displayed extreme volatility, collapsing from a high of 37.00p to a low of 9.22p before recovering to current levels near 14p. This 75% drawdown from peak valuations reflects investor uncertainty regarding the commercialization timeline for the company’s MicroBlate platform, alongside broader sentiment shifts affecting small-cap medtech listings.

Technical Positioning

Short-term technical analysis positions the stock within a wide ascending channel, establishing a floor approximately at 12.40p. London Stock Exchange investor chat forums speculate the shares could test 20p by October, contingent upon US regulatory developments. However, bid-ask spreads remain inconsistently reported across platforms, with snapshots indicating day ranges between 13.00p and 13.50p on certain feeds.

Volume Characteristics

Liquidity patterns show irregular spikes, with recent sessions recording 3.76 million shares traded. Late trades worth £30,000 have been noted by market participants, alongside Friday closing transactions of £46,000. Investors seeking entry should verify execution prices carefully given reported spread inconsistencies.

Understanding precise measurements remains essential across domains, from financial metrics to physical dimensions such as converting 175cm in Feet and Inches.

What are the key fundamentals for Creo Medical shares?

Financial Performance

For the fiscal year ending 31 December 2024, Creo Medical generated £4.00 million in revenue while posting a pre-tax loss of £29.00 million. The adjusted loss per share reached 8.00p, consistent with the company’s developmental-stage profile. First-half 2025 updates indicate improving trajectory, with revenue climbing to £2.2 million from £1.6 million and operating losses narrowing significantly.

Balance Sheet Metrics

The firm’s liquidity position strengthened considerably, with cash reserves climbing to £20.5 million from £8.7 million previously. The current ratio of 2.75 suggests adequate liquidity to cover short-term obligations, while the quick ratio of 0.60 indicates some reliance on inventory conversion. Shareholders’ equity remains negative, with return on assets registering at -35.51%.

Market Valuation

Absence of earnings precludes standard P/E analysis. The stock trades at a price-to-sales multiple between 12.26 and 12.83, and price-to-book between 1.35 and 1.80, reflecting premium valuations assigned to future growth potential rather than current profitability. Yahoo Finance data confirms the market cap at approximately £70.64 million.

What recent news is impacting Creo Medical share price?

Recent corporate developments have generated increased trading activity. On 20 January 2026, the company issued a trading update confirming positive momentum from the first half continuing into the second half of fiscal year 2025. Additionally, management scheduled a Capital Markets Day for 27 October 2025 to present strategic progress to institutional investors.

Clinical Developments

Clinically, Creo Medical achieved a significant milestone by treating the first patient in its MicroBlate Flex lung tumor study. This procedure utilizes the company’s proprietary soft tissue ablation technology, potentially expanding addressable markets beyond gastrointestinal applications into pulmonary oncology, a substantially larger therapeutic area.

Corporate Actions

On 14 January 2026, the company executed awards under its Long-Term Incentive Plan, distributing shares to align management compensation with shareholder value creation. These awards typically vest over multi-year periods contingent upon achieving clinical and commercial milestones.

Is Creo Medical a good investment right now?

Investment suitability depends on risk tolerance and sector expertise. The company offers exposure to advanced surgical technology markets but requires tolerance for significant volatility and continued operational losses. Morningstar’s one-star valuation rating, despite the gap between fair value estimates and current trading prices, signals extreme uncertainty regarding the company’s competitive positioning.

The improved cash runway and narrowing losses provide near-term stability, while the lung cancer application expansion offers genuine catalyst potential. However, regulatory delays or commercialization challenges could pressure the share price further. Investors should conduct due diligence regarding Jobs for 14 Year Olds regulations and other suitability frameworks before committing capital.

What are the upcoming milestones for Creo Medical?

1. 27 October 2025: Capital Markets Day presentation to institutional investors
2. 14 January 2026: Execution of Long-Term Incentive Plan share awards
3. 20 January 2026: FY25 Trading Update confirming second-half momentum

What is certain and what remains uncertain about Creo Medical?

What does Creo Medical Group do?

Creo Medical Group PLC operates as a medical technology company specializing in electrosurgical devices utilizing microwave and radiofrequency energy. The proprietary MicroBlate platform enables precise soft tissue ablation for minimally invasive procedures, primarily targeting gastrointestinal and emerging pulmonary applications. Founded in the United Kingdom and listed on the London Stock Exchange AIM market, the firm maintains research and manufacturing facilities in Chepstow, Wales.

The technology portfolio aims to reduce procedure times and collateral tissue damage compared to conventional surgical methods. Distribution occurs through direct sales forces in the United Kingdom and continental Europe, supplemented by third-party partnerships in other territories. Official investor relations materials emphasize the lung cancer opportunity as a potentially transformative market expansion.

What are market observers saying about Creo Medical?

Independent analysts acknowledge the technology’s clinical potential while cautioning on commercialization risks. Data providers note the extreme volatility relative to broader healthcare sector norms, with sensitivity to speculative news flow exceeding typical small-cap patterns.

The fair value estimate of £4.89 stands at substantial variance to current trading levels, reflecting either deep value opportunity or fundamental business model concerns depending on execution outcomes.

Morningstar Equity Research

Investor sentiment on London Stock Exchange forums has shifted bullish regarding US commercialization potential, though participants acknowledge price targets exceeding 20p remain contingent upon speculative catalysts rather than confirmed contracts.

What is the bottom line for Creo Medical investors?

Creo Medical presents a high-risk, high-reward profile characteristic of developmental-stage medical device enterprises. With shares trading near 14p, the company offers exposure to innovative surgical technology markets but requires investors to accommodate significant volatility and ongoing operational losses. The strengthened cash position and narrowing H1’25 deficits provide interim stability, while pending regulatory decisions and partnership possibilities offer upside catalysts. Those evaluating positions should verify current quotes across multiple brokerage platforms due to reported spread inconsistencies and recognize that sustainable profitability remains several quarters distant.

Frequently Asked Questions